Spiromix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spiromix

Property Description
Active ingredient Spiramycin (a mixture of I, II, and III)
Form Tablet, Powder, Suppository
Pharmacological class Macrolide Antibiotic, Antimicrobial, Antiparasitic
General purpose Manages infections caused by susceptible bacteria and parasites
Origin Natural product (from Streptomyces ambofaciens)

What Type of Medicine is Spiromix?

Spiromix is a prescription-only medicinal product that contains the active ingredient Spiramycin. It is classified as an antimicrobial agent and belongs to the macrolide antibiotic class. Spiramycin, a specific 16-membered ring macrolide, is broadly recognized in clinical practice as an effective compound for combating various susceptible pathogens. This macrolide designation is significant because it provides a reliable option for patients who may not tolerate, or whose infections are resistant to, more common agents like penicillins.


Spiramycin: A Natural Compound and Its Forms

Spiramycin is a natural product derived from the culture broth of the bacterium Streptomyces ambofaciens, establishing its biological origin. This active substance is a complex entity, comprising a mixture of three major components: Spiramycin I, Spiramycin II, and Spiramycin III, all of which contribute to its therapeutic action. As a single-ingredient product, Spiromix is prepared to support flexible routes of administration. The common dosage form(s) include tablets for the oral route, alongside specialized powder preparations and suppositories designed for the injection route (parenteral) and rectal route, respectively.


General Purpose: How Does Spiromix Help?

Spiromix's main purpose is to halt the spread of infectious disease by creating a primarily bacteriostatic effect against susceptible pathogens. This action is achieved by interfering with the bacteria's ability to produce proteins essential for growth and reproduction. The compound has the ability to distribute extensively into tissues, which is a key characteristic compared to other antibiotics. This high tissue distribution helps the medicine concentrate where infections are often present, supporting the body's immune system in overcoming the threat posed by these susceptible organisms.

Regulatory References

  1. Spiramycin - MeSH (Medical Subject Headings)

What side effects are possible with Spiromix?

Possible Side Effects and Safety Information

The safety profile of Spiromix (Spiramycin) is classified by regulatory authorities based on system-organ classes and frequency of occurrence in clinical trials and post-marketing reports. The most Common adverse reactions documented are related to the Gastrointestinal Disorders system, including nausea, vomiting, diarrhea, and abdominal pain or discomfort, which are characteristic effects of the macrolide antibiotic class.


Official Adverse Reaction Groupings

The prescribing information groups potential effects by body system, noting involvement in:

  • Gastrointestinal Disorders: The most frequently reported class of reactions.
  • Hepatobiliary Disorders: Includes the potential for liver abnormalities such as jaundice (yellowing of the skin or eyes) and cholestasis.
  • Skin and Subcutaneous Tissue Disorders: Reactions like skin rash and itching are listed as less common.
  • Cardiac Disorders: Potential effects on heart rhythm are documented.

Serious Safety Considerations

The regulatory documentation highlights the potential for serious adverse reactions, although these are rare. These include cardiac toxicity, specifically the potential for QT prolongation which can lead to irregular heartbeat or fainting (syncope). Other serious, albeit rare, events are severe allergic reactions (including anaphylaxis) and pseudomembranous colitis, a severe form of diarrhea. Pain at the site of injection is also documented for non-oral formulations.


Population-Specific Safety Notes

Safety constraints are explicitly defined for certain patient groups. Individuals with pre-existing hepatic impairment (liver disease or bile duct obstruction) require specific caution and may need regular monitoring of their liver function during treatment. The medicine is contraindicated in patients with known hypersensitivity to Spiramycin or to other antibiotics of the macrolide class.

Overdose and Emergency Response

Spiromix Overdose and When to Seek Help

Overdose information for Spiromix is defined by the documented findings in official government regulatory sources for its active ingredient, Spiramycin. Clinical signs expected following a high dose are generally presented as gastrointestinal disorders, which include nausea, vomiting, and diarrhea.

A more significant and serious manifestation noted in regulatory sources involves the cardiac system, where the occurrence of a prolonged QT interval has been reported. This documented effect carries a risk of potentially severe cardiac outcomes, such as the arrhythmia known as Torsades de pointes.

Immediate medical attention must be sought whenever Spiromix overexposure is suspected. The official emergency response mandated by regulatory authorities requires that an Electrocardiogram (ECG) should be performed immediately upon presentation to assess the severity of the potential cardiac effects.

Regulatory documents explicitly state that no specific antidote is known for Spiramycin overdose. Consequently, the mandated management focuses on providing symptomatic and supportive treatment tailored to the patient's condition. Special attention is directed toward specific populations and risk factors, as cases of prolonged QT interval have been observed in neonates treated with high doses, and patients with existing risk factors, such as hypokalaemia, necessitate heightened monitoring.

Therapeutic Uses of Spiromix

Quick Facts: Spiromix

  • Supports long-term management of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
  • May play a role in reducing the frequency of COPD exacerbations (flare-ups).
  • Provides long-term, daily maintenance for asthma in adults and adolescents (age 12 and older).

Spiromix is indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD), which includes conditions such as chronic bronchitis and emphysema. The medication is used to support the opening of airways and assist in sustaining airflow. Clinical data indicates that Spiromix may also play a role in reducing the likelihood of COPD exacerbations for patients with this condition, contributing to better overall respiratory wellness.

Spiromix is also approved for the long-term, once-daily maintenance treatment of asthma in patients who are 12 years of age and older. This usage is intended to help control symptoms and prevent attacks. It is important to note that Spiromix is intended for maintenance and should not be used for the immediate relief of acute bronchospasm or sudden, severe symptoms.

Eligibility and Restrictions for Use

Who can and cannot use Spiromix?

This section defines the officially documented eligibility rules for Spiromix (Spiramycin) according to regulatory labeling, determining which populations are permitted or restricted from using the medicine.

Contraindications and Restrictions

The primary absolute exclusion is a known Hypersensitivity to spiramycin or any macrolide antibiotic. Individuals with this history must not use the medicine.

Conditional use and caution are required for patients with specific health considerations, including existing risk factors for QT prolongation or pre-existing hepatic impairment. While typically not an absolute contraindication, these conditions necessitate monitoring, as excretion is primarily biliary.

Population Eligibility

Spiromix is generally approved for use in adults, adolescents, and children. Usage in children is common, with dosage determined by weight. Use is not restricted by renal impairment, as the drug has low renal excretion.

Pregnancy and Lactation

Use during pregnancy is conditional and permitted only for the specific treatment of acute maternal toxoplasmosis. However, use is not recommended for individuals who are breastfeeding, as the drug is excreted into human breast milk. The eligibility profile is strictly defined by regulatory bodies based on these risk classifications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of this medicine, which contains a combination of a corticosteroid (fluticasone) and a long-acting beta-agonist (salmeterol), is defined by several categories of co-administered agents.

Interacting Medicines and Categories

Interaction Classification Category or Specific Medicine
Do Not Use Other Long-Acting Beta-Agonists (LABAs), such as formoterol or pure salmeterol.
Use With Caution Potent Cytochrome P450 3A4 (CYP3A4) Inhibitors
Use With Caution Non-Potassium-Sparing Diuretics (e.g., loop or thiazide diuretics)
Use With Caution Beta-Adrenergic Receptor Blocking Agents (Beta-Blockers)
Use With Caution Tricyclic Antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs)

Interaction Constraints

Concomitant Long-Acting Beta-Agonsists (LABAs): The use of other LABAs is not recommended due to the potential for an additive effect that could be harmful.

CYP3A4 Inhibitors: Co-administration with strong inhibitors of the CYP3A4 enzyme, such as certain antivirals (e.g., ritonavir, atazanavir) or antifungals (e.g., ketoconazole, itraconazole), is advised against unless the benefits outweigh the increased risk. These inhibitors can significantly increase the concentration of the fluticasone component.

Beta-Blockers: These agents may diminish or block the bronchodilating effect of the salmeterol component and are typically avoided unless medically necessary.

Diuretics, TCAs, and MAOIs: Use with caution is necessary because these drug classes may increase the risk of certain side effects on the heart or electrolyte balance, such as effects on blood pressure, heart rhythm, or potassium levels.

Mechanism of Action

Targeted Inhibition of Bacterial Growth Machinery

Spiromix's core action is the selective inhibition of bacterial protein synthesis. The active ingredient, Spiramycin, binds non-covalently to the microbial 50S ribosomal subunit , disrupting the translation process by blocking the translocation of the growing protein chain. This key molecular interference results in a bacteriostatic effect that arrests microbial proliferation, allowing host immune mechanisms to function.


Modulation of Local Inflammation and Pathogen Virulence

Beyond the primary antimicrobial mechanism, Spiromix influences host and microbial physiology by modulating key signaling pathways. The drug acts as a modulator on host immune cells, interfering with cascades like NF-**kappa**B activation to help dampen excessive localized inflammation. Furthermore, it reduces the pathogen's ability to produce specific virulence factors, limiting the microbe's capacity to cause tissue damage and modulating the associated inflammatory response.


Constraints and Mechanisms of Functional Specificity

The mechanism's functional range is determined by its high tissue-concentration (ensuring prolonged target saturation) and its susceptibility to microbial resistance. The mechanism is constrained if microbes acquire genes (like erm) that chemically modify the 50S target, rendering the drug unable to bind and exert its inhibitory effect. This highlights how access to and structural integrity of the target site are critical factors that govern the drug's physiological efficacy.

Dosage and Administration Information

How Spiromix is Used: Official Administration Guidelines

Spiromix contains the macrolide antibiotic Spiramycin and is administered according to precise instructions to ensure proper usage. These instructions define the approved administration pathways, standardized dosing ranges, and specific conditions for intake.


Approved Administration Pathways

Spiromix is available in multiple dosage forms to support flexible administration. The officially approved routes include:

  • Oral Route (PO): Used with capsules or tablets.
  • Intravenous Route (IV): Used with the powder that is reconstituted for injection.
  • Rectal Route: Used with suppositories.

Standard Adult Dosing and Frequency

Administration frequency and dose are typically based on the severity and type of infection. Dosing recommendations may vary by region; the following regimens are based on general clinical guidelines:

Infection Severity Administration Route Typical Daily Dose (IU) Frequency
Mild to Moderate Oral 6,000,000 to 9,000,000 IU Divided into 2 or 3 doses
Severe Oral Up to 15,000,000 IU Divided into 2 or 3 doses
Severe Intravenous 3,000,000 IU Every 8 hours

For certain indications, a dose of 12,000,000 to 13,500,000 IU may be administered as a single oral dose.


Conditions for Proper Use

Specific instructions must be followed to ensure correct use of the medicine, which is generally administered without regard to meals. When administering the intravenous form, the reconstituted solution must be injected slowly into a vein. Treatment must be taken for the full prescribed time to complete the course, such as ten days for infections caused by beta-hemolytic streptococci.

  • Population Adjustments: No dosage adjustment is required for adult or pediatric patients with renal impairment (kidney issues).

Recent Clinical Evidence

Evidence for Use in Preventing Mother-to-Child Transmission of Toxoplasma gondii

Research exploring Spiromix during pregnancy centers on whether the drug can affect the mother-to-child transmission (MTCT) of the Toxoplasma gondii parasite. Studies primarily use observational cohort designs, aggregating data through systematic reviews and meta-analyses. Studies explored outcomes such as the rate of parasite transmission and the incidence of congenital toxoplasmosis signs in the infants. Research describes patterns observed in the cohorts, but comparative evidence against multi-drug combination regimens often yields mixed findings. Follow-up for the children typically extends up to three years.

Evidence for Use in Managing Parasitic Diarrhea

Research exploring Spiromix for parasitic gastrointestinal symptoms was studied for chronic diarrhea caused by Cryptosporidiosis in patients with a compromised immune system. Research efforts involved small-scale clinical trials and open-label case series. These studies monitored short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort and laboratory measurements monitoring the clearance of Cryptosporidium oocysts. Studies report how symptoms evolved in the observed populations, but patterns related to parasite load were mixed across trials. The evidence quality varies, and sample sizes were modest, limiting the generalizability of any reported patterns.

Research Limitations and Uncertainty

The research base focuses on two key populations: pregnant women with acute infection and immunocompromised patients with chronic diarrhea. Results apply only to the populations studied, and data for other groups remain insufficient. Certainty remains low due to the limited availability of large, placebo-controlled randomized clinical trials (RCTs) across the drug’s uses. Overall, comparative evidence is lacking for many potential alternatives, and long-term effects are not fully established for either condition. The research provides context but does not determine whether an individual will respond similarly to the patterns observed in the studies.

Frequently Asked Questions (FAQ)

Common questions about Spiromix (FAQ)

Q: How quickly does Spiromix start to work after the first dose?

A: Official information regarding the drug's absorption shows that the active ingredient is absorbed slowly. It typically reaches its highest concentration in the blood about 3 to 4 hours after taking a single oral dose. This concentration pattern is a measure of how the medicine is processed in the body after administration.

Q: Does Spiromix cause weight gain?

A: Official regulatory documents do not typically list weight gain as a commonly reported or expected side effect of the active ingredient, Spiramycin. The most common adverse reactions documented are related to the gastrointestinal system.

Q: What happens if I accidentally miss a dose of Spiromix?

A: Official guidance often describes that if a dose is missed, it is generally recommended to be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the prescribed information typically advises skipping the missed dose to avoid administering doses too close together.

Q: Are there any specific foods or supplements I should avoid while on Spiromix?

A: Regulatory documents state that this medicine is generally administered without regard to meals. However, because the drug is processed by the liver and has potential liver-related side effects, official patient information commonly notes the need to review alcohol use with a healthcare professional.

Q: Why are the use conditions different for [Condition A] vs [Condition B]?

A: The conditions and durations of use differ because Spiromix is indicated for infections caused by two distinct types of pathogens: bacteria and parasites. Each use requires a specific administration regimen intended to maintain the necessary concentration of the medicine for the prescribed duration.

Q: If I am pregnant, what do official sources say about using Spiromix?

A: Official documentation specifies that the use of this medicine during pregnancy is conditional and is permitted only for the specific treatment of acute maternal toxoplasmosis. This indicates a highly restricted use determined by health regulators.

Q: Can Spiromix be used while breastfeeding?

A: According to official regulatory guidance, the use of this medicine is not recommended for individuals who are breastfeeding. This is because the active ingredient has been documented to be excreted into human breast milk.

Q: Why do official documents caution against sudden discontinuation of Spiromix?

A: Patient information from regulatory agencies explains that stopping the antibiotic course too early may lead to the return of the infection. Additionally, failing to complete the full prescribed treatment can contribute to the development of antibiotic resistance.

Q: Are there different inhaler devices for Spiromix?

A: This specific medicine is not an inhaled drug. According to regulatory labeling, it is available in non-inhaled forms, which include tablets for the oral route, specialized powder preparations for injection, and suppositories for rectal administration.

Q: Does Spiromix interact with birth control pills?

A: Spiramycin belongs to the macrolide class of antibiotics. While current clinical guidelines generally suggest that most antibiotics in this class do not reduce the effectiveness of hormonal birth control pills, official documents note that it is important to review all current medications with a healthcare professional.

Q: Is Spiromix safe for older adults (seniors)?

A: Spiromix is approved for use in adults and children, and official prescribing information indicates that dosage adjustments are not required based on age alone. However, caution and monitoring are specifically required for all patients, including older adults, who have pre-existing conditions like hepatic impairment (liver problems).

Q: Does Spiromix affect my ability to drive or operate machinery?

A: Regulatory side effect listings mention some less common effects such as dizziness or fatigue. Official guidance suggests that individuals should note how they respond to the medicine before engaging in activities that require alertness, as these effects may potentially occur.

Q: What is the purpose of the device used to take Spiromix?

A: The medicine is administered in forms like tablets, powder for injection, or suppositories, depending on the route of administration prescribed. The purpose of the delivery method is to ensure the drug reaches the body at the correct site and concentration for treating the target infection.

Q: What is the process for reporting a side effect related to Spiromix?

A: The process involves submitting an adverse reaction report to the national regulatory body responsible for drug safety. Examples include the FDA's MedWatch program in the U.S. or the Yellow Card Scheme in the U.K., which collect data on medicine safety.

Q: Are there different strengths of Spiromix, and why?

A: Official documents define different dose amounts, which are typically based on the severity and specific type of infection being treated. These doses are often expressed in International Units (IU) and are determined by the regulatory bodies.

Q: What should I do if my symptoms seem worse after starting Spiromix?

A: Official patient guidance states that if symptoms do not begin to improve within a few days of starting treatment, or if the symptoms become noticeably worse, consultation with a healthcare professional is necessary.

Q: How does Spiromix compare to using another macrolide antibiotic?

A: Official sources describe Spiromix as a 16-membered macrolide. This structure is noted to give it certain distinct pharmacological properties compared to other macrolides, such as a lower rate of metabolism and the ability to achieve a high concentration in body tissues.

Q: What are the criteria for being 'eligible' to use Spiromix according to regulators?

A: Eligibility is generally defined by having an infection caused by bacteria or parasites that are confirmed or strongly suspected to be susceptible to the active ingredient, Spiramycin. This ensures the medicine is used for its officially approved purposes.

Q: What happens in the body when the effects of Spiromix wear off?

A: The effects wear off as the drug is gradually eliminated from the body. Regulatory information describes that this process occurs primarily through the biliary system, which is supported by its extensive distribution in body tissues.

Q: Can I use alcohol while taking Spiromix?

A: Because the drug is processed by the liver and has the potential for hepatobiliary (liver/bile duct) side effects, official patient information commonly notes that the use of alcohol may be restricted to reduce the potential for an increased risk of side effects.

Q: What are the expectations for symptom improvement on Spiromix?

A: Expectations for improvement depend on the specific condition being treated. For acute bacterial infections, official documents require the full course to be taken for completion. Official documents state that a clinical review may be expected if symptoms do not show improvement within the first few days of treatment.

Q: Are there any known interactions with vaccines and Spiromix?

A: Official drug interaction lists note that antibiotics, including macrolides like Spiromix, may diminish the therapeutic effect of certain live bacterial vaccines, such as the BCG vaccine. It is important to review one's vaccination status with a healthcare professional, as official drug interaction lists note this potential effect.

Q: If I have allergies, can I still use Spiromix?

A: Official documents state that the medicine is contraindicated, meaning it must not be used, in patients who have a known hypersensitivity (severe allergy) to the active ingredient, Spiramycin, or any other macrolide antibiotic.

Q: What is the significance of the research evidence themes reported for Spiromix?

A: The themes reported—such as observational study designs, small sample sizes, and mixed findings—indicate that certainty for some uses remains low. This means the research provides context, but the patterns observed in the studies may not apply to every individual.

Q: Does the time of day matter when using Spiromix?

A: The drug is typically prescribed for two or three divided doses daily. Official patient information often suggests taking the medication around the same time or times every day to help maintain consistent levels of the medicine in the body.

Q: What happens if I use Spiromix more often than the official guidance describes?

A: Official guidance describes that if more than the prescribed dose is accidentally taken, a medical professional should be consulted immediately for prompt assessment and management of any potential risks associated with an excess dose.

How should Spiromix be stored and disposed of?

How to Store and Dispose of Spiromix

Official regulatory documents define strict environmental and handling requirements to maintain the stability of Spiromix (Tiotropium inhalation).


Storage Requirements

  • Temperature: Store at Controlled Room Temperature (25 C / 77 F); avoid freezing and temperatures exceeding 30 C (86 F).
  • Protection: Keep the medicine away from excessive moisture, heat, and direct light.
  • Packaging: Keep inhalation capsules sealed in the original blister pack until the moment of immediate use.
  • Child Safety: Store the product strictly out of the reach of children and pets.

Disposal Instructions

  • In-Use Device Life: The Respimat inhaler device must be discarded after three months from its first use, regardless of remaining doses.
  • Post-Use: Used capsules must be immediately removed and discarded from the inhaler device.
  • General: Dispose of any unused or expired product according to local pharmaceutical waste guidelines, often involving a pharmacist or a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spiromix found in:

A-Z Index: